Florence Nguyen-Khac

List of Publications by Year
in descending order

73	3,545	186209 28	138417 58
papers	citations	h-index	g-index

78	78	78	5580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. Haematologica, 2022, 107, 593-603.	1.7	18
2	The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia, 2022, 36, 1451-1466.	3.3	14
3	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. Biomolecules, 2022, 12, 901.	1.8	2
4	A fixed-duration, measurable residual diseaseâ€“guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial. Blood, 2021, 137, 1019-1023.	0.6	10
5	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	0.6	30
6	Clinical and biological features of Bâ€cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. British Journal of Haematology, 2021, 193, 72-82.	1.2	8
7	Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort. Annals of Hematology, 2021, 100, 987-993.	0.8	23
8	Acquisition of TCF3 and CCND3 Mutations and Transformation to Burkitt Lymphoma in a Case of B-Cell Prolymphocytic Leukemia. HemaSphere, 2021, 5, e563.	1.2	2
9	Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: A study of the French Innovative Leukemia Organization. American Journal of Hematology, 2021, 96, E311-E314.	2.0	7
10	Cytogenetic and molecular abnormalities in <scp>W</scp>aldenstrÃ¶m's macroglobulinemia patients: Correlations and prognostic impact. American Journal of Hematology, 2021, 96, 1569-1579.	2.0	22
11	â€œDouble-Hitâ€•Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes. Frontiers in Oncology, 2021, 11, 826245.	1.3	3
12	Recommendations for cytogenomic analysis of hematologic malignancies: comments from the Francophone Group of Hematological Cytogenetics (GFCH). Leukemia, 2020, 34, 1711-1713.	3.3	5
13	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. American Journal of Hematology, 2020, 95, 1361-1367.	2.0	20
14	Identification of two DNA methylation subtypes of WaldenstrÃ¶m's macroglobulinemia with plasma and memory B cell features. Blood, 2020, 136, 585-595.	0.6	10
15	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. Blood Cancer Journal, 2020, 10, 38.	2.8	7
16	Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multi-center study. Haematologica, 2020, 106, 87-97.	1.7	43
17	Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2019, 6, e470-e479.	2.2	20
18	Isolated isochromosomes i(X)(p10) and idic(X)(q13) are associated with myeloid malignancies and dysplastic features. American Journal of Hematology, 2019, 94, E285-E288.	2.0	2

#	Article	IF	Citations
19	Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53. Blood, 2019, 134, 1821-1831.	0.6	18
20	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drugâ€resistant chronic lymphocytic leukemia. Cancer Medicine, 2019, 8, 3131-3141.	1.3	10
21	A Recurrent Activating Missense Mutation in WaldenstrÃ¶m Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. Cancer Discovery, 2019, 9, 796-811.	7.7	30
22	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities. World Neurosurgery, 2019, 125, 339-342.	0.7	1
23	Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1â€“derived peptides overcomes drug resistance. Blood Advances, 2019, 3, 2920-2933.	2.5	11
24	Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia. Haematologica, 2019, 104, 1150-1155.	1.7	14
25	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood, 2019, 133, 1205-1216.	0.6	164
26	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology,the, 2018, 5, e82-e94.	2.2	23
27	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica, 2018, 103, e158-e161.	1.7	16
28	â€œDoubleâ€hitâ€•chronic lymphocytic leukemia: An aggressive subgroup with 17p deletion and 8q24 gain. American Journal of Hematology, 2018, 93, 375-382.	2.0	13
29	Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group. Genes Chromosomes and Cancer, 2018, 57, 533-540.	1.5	18
30	Chronic lymphocytic leukaemia genomics and the precision medicine era. British Journal of Haematology, 2017, 178, 852-870.	1.2	12
31	Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1. Leukemia, 2017, 31, 1625-1629.	3.3	38
32	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. Leukemia, 2017, 31, 1547-1554.	3.3	46
33	Drug-perturbation-based stratification of blood cancer. Journal of Clinical Investigation, 2017, 128, 427-445.	3.9	124
34	Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogÃ©nÃ©tique hÃ©matologique (GFCH). Annales De Biologie Clinique, 2016, 74, 561-567.	0.2	6
35	Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. Haematologica, 2016, 101, e299-e302.	1.7	35
36	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica, 2016, 101, 959-967.	1.7	57

#	Article	IF	Citations
37	Chronic lymphocytic leukemia: Time to go past genomics?. American Journal of Hematology, 2016, 91, 518-528.	2.0	13
38	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood, 2015, 125, 856-859.	0.6	70
39	Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood, 2015, 126, 2110-2117.	0.6	94
40	Antiviral therapy is associated with a better survival in patients with hepatitis C virus and Bâ€cell nonâ€Hodgkin lymphomas, ANRS HCâ€13 lymphoâ€C study. American Journal of Hematology, 2015, 90, 197-203.	2.0	84
41	CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCÎ³1 Activation: Evidence from Mice and Humans. PLoS Medicine, 2015, 12, e1001796.	3.9	65
42	Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia, 2014, 28, 230-233.	3.3	51
43	Sex chromosome loss may represent a diseaseâ€associated clonal population in chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2014, 53, 240-247.	1.5	22
44	14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma. Genes Chromosomes and Cancer, 2014, 53, 657-666.	1.5	25
45	Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: A systematic reappraisal of classic cytogenetic data. American Journal of Hematology, 2014, 89, 249-255.	2.0	113
46	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. Cancer Discovery, 2014, 4, 1088-1101.	7.7	213
47	Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. Haematologica, 2013, 98, 649-654.	1.7	119
48	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98, 1748-1752.	1.7	50
49	LHX2 deregulation by juxtaposition with the IGH locus in a pediatric case of chronic myeloid leukemia in B-cell lymphoid blast crisis. Leukemia Research, 2012, 36, e195-e198.	0.4	5
50	Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies. Leukemia, 2012, 26, 2027-2031.	3.3	27
51	Chronic lymphocytic leukemia and prolymphocytic leukemia with MYC translocations: a subgroup with an aggressive disease course. Annals of Hematology, 2012, 91, 863-873.	0.8	65
52	Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. Blood, 2011, 117, 6109-6119.	0.6	62
53	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	7.7	792
54	Concomitant telomere shortening, acquisition of multiple chromosomal aberrations and in vitro resistance to apoptosis in a single case of progressive CLL. Leukemia Research, 2011, 35, e37-e40.	0.4	3

#	Article	IF	Citations
55	Functional assessment of p53 in chronic lymphocytic leukemia. Blood Cancer Journal, 2011, 1, e5-e5.	2.8	13
56	Specific chromosomal IG translocations have different prognoses in chronic lymphocytic leukemia. American Journal of Blood Research, 2011, 1, 13-21.	0.6	15
57	Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood, 2010, 116, 239-249.	0.6	31
58	Chromosomal abnormalities in transformed Phâ€negative myeloproliferative neoplasms are associated to the transformation subtype and independent of JAK2 and the TET2 mutations. Genes Chromosomes and Cancer, 2010, 49, 919-927.	1.5	15
59	Gain of the short arm of chromosome 2 (2p) is a frequent recurring chromosome aberration in untreated chronic lymphocytic leukemia (CLL) at advanced stages. Leukemia Research, 2010, 34, 63-68.	0.4	61
60	Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELBin an aggressive subset of chronic lymphocytic leukemia in males. BMC Medical Genomics, 2010, 3, 53.	0.7	15
61	Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia, 2010, 24, 201-203.	3.3	43
62	Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia, 2010, 24, 246-251.	3.3	11
63	A new recurrent translocation t(11;14)(q24;q32) involving IGH@ and miR-125b-1 in B-cell progenitor acute lymphoblastic leukemia. Leukemia, 2010, 24, 1362-1364.	3.3	82
64	Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters. Blood, 2010, 116, 4588-4590.	0.6	36
65	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. Annals of Hematology, 2009, 88, 1215-1221.	0.8	23
66	The most frequent t(14;19)(q32;q13)-positive B-cell malignancy corresponds to an aggressive subgroup of atypical chronic lymphocytic leukemia. Leukemia, 2008, 22, 2123-2127.	3.3	47
67	Absence of microsatellite instability in human chronic lymphocytic leukaemia B cells. Leukemia, 2008, 22, 186-189.	3.3	2
68	Transcriptional activation of the cardiac homeobox gene CSX1/NKX2-5 in a B-cell chronic lymphoproliferative disorder. Haematologica, 2008, 93, 1081-1085.	1.7	7
69	Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Blood, 2007, 109, 3451-3461.	0.6	188
70	Trisomy 4, a new chromosomal abnormality in WaldenstrÃ¶m's macroglobulinemia: a study of 39 cases. Leukemia, 2006, 20, 1634-1636.	3.3	64
71	MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Human Molecular Genetics, 2006, 15, 933-942.	1.4	116
72	Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genetics and Cytogenetics, 2005, 159, 74-78.	1.0	8

#	Article	IF	Citations
73	Trisomy 4 associated with double minute chromosomes and MYC amplification in acute myeloblastic leukemia. Annales De GÃ©nÃ©tique, 2004, 47, 423-427.	0.4	11